Cellular Origins acquires Actia Platform IP to enhance automated cell therapy manufacturing

FHS
July 2, 2024
10:06 am

Cellular Origins, a TTP Company, focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies (CGTs), today announced the acquisition of the ACTIA (Autologous Cell Therapy Industrial Automation) Platform IP, developed by Geoff Hodge whilst CEO of SOTIO Biotech US. The ACTIA Platform complements Cellular Origins’ existing approach and will accelerate and expand R&D efforts to further develop the Company’s robotic solution for automated cell therapy manufacturing, Constellation™.

Interdisciplinary team reveals how Porphyromonas gingivalis interferes with chemotherapy-induced mitophagy

A new paper from an interdisciplinary team at MUSC Hollings Cancer Center describes how the bacteria Porphyromonas gingivalis interferes with chemotherapy-induced mitophagy, allowing oral cancer

June 18, 2024

VA Health Chat Now Available Nationwide, Connecting 6.8M Veterans with On-Demand Virtual Care

What You Should Know: – Veterans across the United States can now access convenient, on-demand healthcare through VA Health Chat, following the platform’s national rollout

June 6, 2024

Clinical trials exclude disabled Americans because federal agencies failed them, new report finds

People with disabilities are largely excluded from clinical trials that could benefit them because federal agencies have failed to update rules that govern how trials

August 15, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.